Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Key facts
- Who runs it
- Hospital Moinhos de Vento
- Where
- Brazil29 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 107 people enrolled
- Started
- 27 Jan 2022
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Duration of therapy
- Record updated
- 6 March 2024
- Why it stopped
- low recruitment rate
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Infection's diagnosis while in the ICU
- Severe infection in any site (defined as the presence of sepsis/septic shock or bloodstream infection or pneumonia) associated with a positive culture by MRD-GNB (Acinetobacter baumannii complex, Pseudomonas aeruginosa, and Enterobacterales bacteria, only susceptible to carbapenems and/or polymyxins)
- Hemodynamically stable and afebrile (axillary temperature less than 37.8ºC) for at least 48 hours on day 7 of adequate antibiotic therapy
- Consent of the team providing care to the patient regarding their inclusion in the research
Who cannot take part
- Inclusion in other experimental studies involving antimicrobial therapy
- Positive blood cultures for the same pathogen within 48 hours prior to randomization, when collected
- Uncontrolled concomitant infection with another GNB (regardless of susceptibility profile)
- Previous inclusion in this study
- Infections that have as the primary site: endocarditis/endovascular infection, necrotizing fasciitis, osteomyelitis, abdominal abscess or other abdominal infections requiring surgical intervention (except infections that have been treated surgically, with curative character within the first 3 days of appropriate antimicrobial therapy), central nervous system Infections, empyema, prosthetic infection
- Immunosuppression defined as: neutrophil cells <1000/mm³ in the current hospitalization, HIV/AIDS diagnosis with last CD4 count <200/mm³, solid organ transplantation in the last year and/or need for increased immunosuppression due to acute rejection in the last year, hematopoietic stem cell transplantation in the last year, and/or current therapy for chronic graft-versus-host disease
- Known pregnancy
- Patient in palliative care who has already decided not to restart antimicrobials, if necessary, or hemodynamic support measures
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the most common pathogens associated with multidrug resistance and HAIs. These bacteria are of special concern because few therapeutic options are available.
Read full original descriptionShow less
Traditionally, the duration of treatment for severe multidrug-resistant (MDR)-GNB infections is 14 days. Studies of severe infections by GNB, regardless of susceptibility profile, have shown that shorter antimicrobial treatments are not inferior to traditional durations of therapy and are associated with a lower incidence of adverse effects. However, there are currently no studies assessing whether shorter duration of antimicrobial treatment is effective for MDR-GNB.
This open-label, randomized clinical trial aims to assess the non-inferiority of 7-day antibiotic therapy compared to conventional 14-day treatment in severe infections by MDR-GNB.
The 2 groups in the trial
- 7-day adequate antibiotic therapyTreatment being tested
Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
Treatment: Duration of therapy
- 14-day adequate antibiotic therapyExisting treatment, for comparison
Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
Treatment: Duration of therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Open-label, Randomized Clinical Trial to Assess the Non-inferiority of 7-day Antibiotic Therapy Compared to Conventional 14-day Treatment in Multidrug-resistant Gram-negative Bacilli Infections
- Record updated
- 6 March 2024